1. Circulating predictive markers of immune checkpoint inhibitors in non-small cell lung cancer
    A. A. Musaelyan et al, 2021, Advances in Molecular Oncology CrossRef
  2. PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
    Sandra Lassalle et al, 2020, International Journal of Molecular Sciences CrossRef
  3. TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model
    Nourridine Siewe et al, 2021, PLOS ONE CrossRef
  4. Quantifying the contribution of transcription factor activity, mutations and microRNAs to CD274 expression in cancer patients
    Imke B. Bruns et al, 2022, Scientific Reports CrossRef
  5. Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports
    Farkhad Manapov et al, 2023, Expert Opinion on Investigational Drugs CrossRef
  6. Luptând cu boala la 83 de ani: supravieţuire în cazul infecţiei cu SARS-CoV-2 la o pacientă cu adenocarcinom pulmonar PD-L1 negativ, care a răspuns la tratament anti-PD-1 – prezentare de caz
    Maria Nedelcu et al, 2022, Oncolog-Hematolog.ro CrossRef
  7. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
    Li-Chung Chiu et al, 2021, Vaccines CrossRef
  8. An Overview of Promising Biomarkers in Cancer Screening and Detection
    Saba Hasan, 2020, Current Cancer Drug Targets CrossRef
  9. Advanced Melanoma
    Alexandra M. Haugh et al, 2021, Hematology/Oncology Clinics of North America CrossRef
  10. Checkpoint Molecules in Rheumatology—or the Benefits of Being Exhausted
    Stinne Ravn Greisen et al, 2021, Current Rheumatology Reports CrossRef
  11. Targeting immune checkpoint pathways in melanoma: triumphs and challenges
    Patricia Ines Back et al, 2023, Future Drug Discovery CrossRef
  12. Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability
    Katiane Tostes et al, 2023, International Journal of Molecular Sciences CrossRef
  13. Editorial: Application of artificial intelligence in improving immunotherapeutic efficacy
    Jie Li et al, 2022, Frontiers in Pharmacology CrossRef
  14. Prognostic and Predictive Markers for Immunotherapy in Non Small Cell Lung Cancer
    null null et al, 2023, Journal of Medical and Radiation Oncology CrossRef